Search Results - "Cottu, Paul H"

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers by Cottu, Paul H, Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M, Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S, Gilles, Erard M, Proniuk, Stefan, Dieras, Veronique, Jackson, David M, Zukiwski, Alexander, Italiano, Antoine

“…Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical…”
Get full text

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design by Di Meglio, Antonio, Martin, Elise, Crane, Tracy E, Charles, Cecile, Barbier, Aude, Raynard, Bruno, Mangin, Anthony, Tredan, Olivier, Bouleuc, Carole, Cottu, Paul H, Vanlemmens, Laurence, Segura-Djezzar, Carine, Lesur, Anne, Pistilli, Barbara, Joly, Florence, Ginsbourger, Thomas, Coquet, Bernadette, Pauporte, Iris, Jacob, Guillemette, Sirven, Aude, Bonastre, Julia, Ligibel, Jennifer A, Michiels, Stefan, Vaz-Luis, Ines

“…Elevated body mass index (BMI) represents a risk factor for cancer-related fatigue (CRF). Weight loss interventions are feasible and safe in cancer survivors,…”
Get full text

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study by Di Meglio, Antonio, Michiels, Stefan, Jones, Lee W., El-Mouhebb, Mayssam, Ferreira, Arlindo R., Martin, Elise, Matias, Margarida, Lohmann, Ana Elisa, Joly, Florence, Vanlemmens, Laurence, Everhard, Sibille, Martin, Anne-Laure, Lemonnier, Jerome, Arveux, Patrick, Cottu, Paul H., Coutant, Charles, Del Mastro, Lucia, Partridge, Ann H., André, Fabrice, Ligibel, Jennifer A., Vaz-Luis, Ines

“…Evidence on how weight loss correlates to health-related quality-of-life (HRQOL) among obese breast cancer (BC) patients is limited. We aimed to evaluate…”
Get full text

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk by Pistilli, Barbara, Paci, Angelo, Ferreira, Arlindo R, Di Meglio, Antonio, Poinsignon, Vianney, Bardet, Aurelie, Menvielle, Gwenn, Dumas, Agnes, Pinto, Sandrine, Dauchy, Sarah, Fasse, Leonor, Cottu, Paul H, Lerebours, Florence, Coutant, Charles, Lesur, Anne, Tredan, Olivier, Soulie, Patrick, Vanlemmens, Laurence, Jouannaud, Christelle, Levy, Christelle, Everhard, Sibille, Arveux, Patrick, Martin, Anne Laure, Dima, Alexandra, Lin, Nancy U, Partridge, Ann H, Delaloge, Suzette, Michiels, Stefan, André, Fabrice, Vaz-Luis, Ines

“…Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence…”
Get full text

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients by Chargari, Cyrus, Kirova, Youlia M., Diéras, Véronique, Pena, Pablo Castro, Campana, Francois, Cottu, Paul H., Pierga, JeanYves, Fourquet, Alain

“…Preclinical data have demonstrated that ionizing radiation acts synergistically with capecitabine. This report retrospectively assessed the use of capecitabine…”
Get full text

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer by Meyniel, Jean-Philippe, Cottu, Paul H, Decraene, Charles, Stern, Marc-Henri, Couturier, Jérôme, Lebigot, Ingrid, Nicolas, André, Weber, Nina, Fourchotte, Virginie, Alran, Séverine, Rapinat, Audrey, Gentien, David, Roman-Roman, Sergio, Mignot, Laurent, Sastre-Garau, Xavier

“…The distinction between primary and secondary ovarian tumors may be challenging for pathologists. The purpose of the present work was to develop genomic and…”
Get full text

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy by Di Meglio, Antonio, Havas, Julie, Gbenou, Arnauld S, Martin, Elise, El-Mouhebb, Mayssam, Pistilli, Barbara, Menvielle, Gwenn, Dumas, Agnes, Everhard, Sibille, Martin, Anne-Laure, Cottu, Paul H, Lerebours, Florence, Coutant, Charles, Lesur, Anne, Tredan, Olivier, Soulie, Patrick, Vanlemmens, Laurence, Joly, Florence, Delaloge, Suzette, Ganz, Patricia A, André, Fabrice, Partridge, Ann H, Jones, Lee W, Michiels, Stefan, Vaz-Luis, Ines

“…We aimed to characterize long-term quality of life (QOL) trajectories among patients with breast cancer treated with adjuvant chemotherapy and to identify…”
Get full text

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis by Vaz-Luis, Ines, Di Meglio, Antonio, Havas, Julie, El-Mouhebb, Mayssam, Lapidari, Pietro, Presti, Daniele, Soldato, Davide, Pistilli, Barbara, Dumas, Agnes, Menvielle, Gwenn, Charles, Cecile, Everhard, Sibille, Martin, Anne-Laure, Cottu, Paul H, Lerebours, Florence, Coutant, Charles, Dauchy, Sarah, Delaloge, Suzette, Lin, Nancy U, Ganz, Patricia A, Partridge, Ann H, André, Fabrice, Michiels, Stefan

“…Fatigue is recognized as one of the most burdensome and long-lasting adverse effects of cancer and cancer treatment. We aimed to characterize long-term fatigue…”
Get full text

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification by Ng, Charlotte K Y, Martelotto, Luciano G, Gauthier, Arnaud, Wen, Huei-Chi, Piscuoglio, Salvatore, Lim, Raymond S, Cowell, Catherine F, Wilkerson, Paul M, Wai, Patty, Rodrigues, Daniel N, Arnould, Laurent, Geyer, Felipe C, Bromberg, Silvio E, Lacroix-Triki, Magali, Penault-Llorca, Frederique, Giard, Sylvia, Sastre-Garau, Xavier, Natrajan, Rachael, Norton, Larry, Cottu, Paul H, Weigelt, Britta, Vincent-Salomon, Anne, Reis-Filho, Jorge S

“…HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2…”
Get full text

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane by Vanacker, Hélène, Treilleux, Isabelle, Schiffler, Camille, Bieche, Ivan, Campone, Mario, Patsouris, Anne, Arnedos, Monica, Cottu, Paul H., Jacquin, Jean-Philippe, Dalenc, Florence, Pinton, Antoine, Servant, Nicolas, Attignon, Valéry, Rouleau, Etienne, Morel, Alain, Legrand, François, Jimenez, Marta, Andre, Fabrice, Bachelot, Thomas

“…Background To identify patients most likely to respond to everolimus, a mammalian target of rapamycin (mTOR) inhibitor, a prospective biomarker study was…”
Get full text

Systemic neoadjuvant therapy of luminal breast cancer in 2016 by Cottu, Paul H

“…Neoadjuvant systemic therapies have been extensively evaluated in luminal breast cancer. Conventional cytotoxic chemotherapy increases breast conservation…”
Get more information

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity by Lewis, James H., Cottu, Paul H., Lehr, Martin, Dick, Evan, Shearer, Todd, Rencher, William, Bexon, Alice S., Campone, Mario, Varga, Andrea, Italiano, Antoine

“…Introduction Antiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the…”
Get full text

Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study by Le Saux, Olivia, Lardy-Cleaud, Audrey, Frank, Sophie, Debled, Marc, Cottu, Paul H., Pistilli, Barbara, Vanlemmens, Laurence, Leheurteur, Marianne, Lévy, Christelle, Laborde, Lilian, Uwer, Lionel, D'hondt, Veronique, Berchery, Delphine, Lorgis, Veronique, Ferrero, Jean-Marc, Perrocheau, Genevieve, Courtinard, Coralie, Mouret-Reynier, Marie Ange, Velten, Michel, Breton, Mathias, Parent, Damien, Chabaud, Sylvie, Robain, Mathieu, Bachelot, Thomas

“…For luminal metastatic breast cancer (MBC), endocrine therapy (ET) is the recommended initial treatment before chemotherapy. Our objective was to evaluate the…”
Get full text

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France by Hurtaud, Aline, Donnadieu, Anne, Escalup, Laurence, Cottu, Paul H, Baffert, Sandrine

“…Abstract Background There is no standard recommendation for metastatic breast cancer treatment (MBC) after two chemotherapy regimens. Eribulin (Halaven® ) has…”
Get full text

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas by Rodrigues, Manuel Jorge, Wassermann, Johanna, Albiges, Laurence, Brain, Etienne, Delaloge, Suzette, Stevens, Denise, Guinebretière, Jean-Marc, Mathieu, Marie-Christine, Kirova, Youlia, Guillot, Eugénie, Vincent-Salomon, Anne, Cottu, Paul H

Get full text

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines by HOANG, J.-M, COTTU, P. H, THUILLE, B, SALMON, R. J, THOMAS, G, HAMELIN, R

“…Instability of microsatellites is a hallmark of the DNA replication error phenotype (RER+) due to the inactivation of mismatch repair genes. In humans,…”
Get full text

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy by Kriegel, Irène, Cottu, Paul H, Fourchotte, Virginie, Sanchez, Sebastian, Fromantin, Isabelle, Kirov, Krassen, Guillaume, Alain, Pelloquin, Anne, Esteve, Marc, Salmon, Remy J

“…The aim of this study was to determine, in a population with metastatic breast cancer treated with bevacizumab therapy, the incidence of wound dehiscence after…”
Get full text

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients by Chargari, Cyrus, Kirova, Youlia M., Diéras, Véronique, Castro Pena, Pablo, Campana, Francois, Cottu, Paul H., Pierga, JeanYves, Fourquet, Alain

“…The online version of the original article can be found under doi: 10.1007/s11060-008-9791-2…”
Get full text

Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience by Gachet, Julie, Giroux, Julie, Girre, Véronique, Brain, Étienne, Kirova, Youlia, Mignot, Laurent, Mazeron, Jean-Jacques, Dutertre, Guillaume, Pouit, Bernard, Mosseri, Véronique, Falcou, Marie-Christine, Cottu, Paul H

“…Breast cancer is the second cause for brain metastases. Their incidence is rising, partly due to the therapeutic improvements which alter the natural history…”
Get more information

Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients by Bouleuc, Carole, Burnod, Alexis, Cottu, Paul H., Pierga, Jean-Yves, Dolbeault, Sylvie

“…Abstract only 12110 Background: Accuracy of prognosis perception is a key element to allow advanced cancer patients to make informed decisions and to reflect…”
Get full text